Jounce Therapeutics, Inc. (NASDAQ:JNCE) reported earnings of ($0.11) per share beating Walls Streets expectations.

ME Staff
-
0

Jounce Therapeutics, Inc. (NASDAQ:JNCE) reported Q2 2017 earnings this Morning, coming in at ($0.11) per share, beating Wall Street’s estimates of ($0.15) per Share. Revenue for the quarter came in at $20.29 million beating analyst estimates of $19.94 million

Analyst Coverage For Jounce Therapeutics, Inc. (NASDAQ:JNCE)
These are 4 Buy Ratings .
The current consensus rating for Jounce Therapeutics, Inc. (NASDAQ:JNCE) is Buy (Score: 3.00) with a consensus target price of $29.00 , a potential (143.49% upside)

Recent Insider Trading for Jounce Therapeutics, Inc. (NASDAQ:JNCE)

  • On 2/1/2017 Celgene Switzerland Llc, Major Shareholder, bought 625,000 with an average share price of $16.00 per share and the total transaction amounting to $10,000,000.00.
  • On 2/1/2017 John Duncan Higgons, Director, bought 6,700 with an average share price of $16.00 per share and the total transaction amounting to $107,200.00.



    Recent Trading for Jounce Therapeutics, Inc. (NASDAQ:JNCE)
    Shares of Jounce Therapeutics, Inc. closed the previous trading session at 11.38 down -0.53 -4.45% with 178,815 shares trading hands.